

ENANTA PHARMACEUTICALS INC
Form 8-K
March 02, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 28, 2018

ENANTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35839 04-3205099
(State or other jurisdiction (Commission (IRS Employer

of incorporation) File Number) Identification No.)

500 Arsenal Street, Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(617) 607-0800

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17, CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting held on February 28, 2018, Enanta's stockholders voted on the following proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 19, 2018.

Proposal No. 1: To Elect Three Class II Directors to Serve Until the 2021 Annual Meeting of Stockholders.

The stockholders re-elected the following individuals as Class II directors of the Company:

| Name of Director Nominee | Votes For | Broker | |
|-----------------------------|------------|----------------|-----------|
| | | Votes Withheld | Non-Votes |
| George S. Golumbeski, Ph.D. | 7,906,803 | 6,293,582 | 1,522,744 |
| Kristine Peterson | 13,793,479 | 406,906 | 1,522,744 |
| Terry C. Vance | 14,146,357 | 54,028 | 1,522,744 |

Proposal No. 2: To Ratify the Appointment of Enanta's Independent Registered Public Accounting Firm.

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2018.

| Votes For | Votes | | Broker | |
|------------|---------|---------|-----------|--|
| | Against | Abstain | Non-Votes | |
| 15,697,073 | 23,181 | 2,875 | 0 | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 2, 2018 ENANTA PHARMACEUTICALS, INC.

By: /s/ Paul J. Mellett
Paul J. Mellett

Senior Vice President, Finance and Administration and Chief Financial Officer